Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Wideman who wrote (2054)	7/25/1998 12:15:00 PM
From: G.P.	Read Replies (1) \| Respond to of 4028

For Long-Term Investors... E-Mail from Dell: Dear Sirs, > I am a long term investor in CYGS and and was wondering if you would care to comment on the following: > 1) Any new products in the pipeline? > > 2) When does the animal testing phase begin for telovector, or if begun, when do you anticipate results? > > 3) Is aquaculture, "Heartland Project" being scrapped in light of recent announcements? If not, could you give update as to where you are on this project. Is "master franchise unit" still being worked on and if so, when do you anticipate completion? Thank-you. > Sincerely, > GP Dear GP Thank you for your interest in and support of CYGS. To answer your ???'s: 1) As long as Mike Skillern is around, there will always be new products under development as there are now, but none that we can announce or discuss at this time. Mike is a veritable Amazon flow of ideas for products in many areas, not just biotechnology. In fact his long and strong suit is quantum physics, not biology. 2) We don't have a firm date on animal testing at this time. We will of course announce such testing when we know the schedule for that is one of the serious milestones in biotech research. 3) The "HeartLand" project has not been scrapped. It has been sidetracked for the moment while some additional research into optimum densities is completed and that's OK because the urgency of getting the ssDNA expression vector into the main stream is so important, not just for equity value, but more importantly for the significance that gene based therapies like antisense will have on healthcare accross the board. The underlying objective of CYGS is to help eliminate disease and if we can do that all CYGS shareholders derserve to share in the considerable rewards success will offer. Getting back to Heartland -- the "master Franchise Unit" (or "company store" as I call it) is still in the design phase. We are having to design and even invent some elements to most efficiently incorporate the new technology that will be central to our toxin free "clean room" approach to mariculture. We still plan to set it up as an autonomous division when appropriate. We are in the process of setting up a Company Bulletin Board on the website where thoughtful inquiries like yours can be posted along with our replies. Again, we especially appreciate the continued support of our long time investors. Call or email any time. Dell Gibson Exec VP, IR